Home New England Cambridge, MA Immuneering COMPANY
Clinical Phase 3
3 open jobs · last seen Oct 23, 2026 · 5 sources
Keywords: oncology cancer pancreatic cancer lung cancer Pancreatic Adenocarcinoma Malignant Melanoma (Cutaneous) Pancreatic Cancer Metastatic PDAC - Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma Pancreatic Adenocarcinoma Metastatic Non-small Cell Lung Cancer Pancreas Adenocarcinoma IMM-6-415 Show all 13 keywords
Profile checked Oct 10, 2026
Hiring Title Location (from posting) Employer posted First seen Associate Director, Formulation Development Cambridge, MA, US; New York, NY, US; San Diego, CA, US Sep 21, 2026 Oct 11, 2026 Director, Regulatory CMC Remote/Home Work; Cambridge, MA, US; New York, NY, US; Thornmint, San Diego, CA, US Sep 2, 2026 Oct 11, 2026 Director, Pharmacovigilance Location not stated Jul 9, 2026 Oct 11, 2026
See all 3 jobs
At a glance Region New England Stage Clinical Phase 3 Latest trial Phase 3: Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma (Jun 5, 2026) source Timeline Jun 5, 2026 Trial start Phase 3: Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma source ↗ Sep 25, 2025 Raise Follow-on offering: $175M (total, as published), announced Sep 25, 2025. Source: company release on GlobeNewswire. source ↗ Aug 26, 2025 Raise Private placement: $25M (total, as published), announced Aug 26, 2025. Source: company release on GlobeNewswire. source ↗ Feb 27, 2024 Trial start Phase 1/Phase 2: A Study of IMM-6-415 in RAS/RAF Mutant Solid Tumors source ↗ Oct 31, 2022 Trial start 1: A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors source ↗ Upcoming milestones 2028-06 (ESTIMATED) · Phase 3 · Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma · NCT07562152 Estimated primary completion per ClinicalTrials.gov. Dates move.
Funding Raised: $200.0M. Last 2 years.
Sep 25, 2025 Follow-on offering: $175M (total, as published), announced Sep 25, 2025. Source: company release on GlobeNewswire. source ↗ Aug 26, 2025 Private placement: $25M (total, as published), announced Aug 26, 2025. Source: company release on GlobeNewswire. source ↗ Clinical trials (lead sponsor) 3 Record Title Phase Status Start Primary completion NCT07562152 Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma Phase 3 Recruiting Jun 5, 2026 2028-06 (estimated) NCT05585320 A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors 1 Active, not recruiting Oct 31, 2022 2026-06 (estimated) NCT06208124 A Study of IMM-6-415 in RAS/RAF Mutant Solid Tumors Phase 1/Phase 2 Completed Feb 27, 2024 Apr 30, 2025 (actual)
Raises and investors new Form D raises come from the company’s own SEC filing (last 2 years).
2025-09-09 Raise Private raise (SEC Form D): $25.0M sold; issuer “Immuneering Corp”. Verified from the SEC filing. SEC filing ↗ Open jobs 3 Title Location (from posting, not HQ) Employer posted First seen Level Associate Director, Formulation Development Cambridge, MA, US; New York, NY, US; San Diego, CA, US Sep 21, 2026 Oct 11, 2026 Senior Description Director, Regulatory CMC Remote/Home Work; Cambridge, MA, US; New York, NY, US; Thornmint, San Diego, CA, US Sep 2, 2026 Oct 11, 2026 Senior Description Director, Pharmacovigilance Not listed Jul 9, 2026 Oct 11, 2026 Senior Description
Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.
Connect See your connections at Immuneering on LinkedIn (search by name, results not checked) LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.
LinkedIn page linked from the company's own site: source · seen 2026-10-18
